Robafen DM, Generic for Robitussin DM, In each teaspoonful (5mL): Dextromethorphan HBr, USP 10mg,...
FDA Drug Recall #D-1410-2019 — Class II — June 10, 2019
Recall Summary
| Recall Number | D-1410-2019 |
| Classification | Class II — Moderate risk |
| Date Initiated | June 10, 2019 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Preferred Pharmaceuticals, Inc |
| Location | Anaheim, CA |
| Product Type | Drugs |
| Quantity | 192 4 oz bottles |
Product Description
Robafen DM, Generic for Robitussin DM, In each teaspoonful (5mL): Dextromethorphan HBr, USP 10mg,/Guaifenesin, USP 100mg, 118mL (4oz) bottle, Manufactured for Preferred Pharmaceuticals, Inc., Anaheim, CA 92807 by Major Pharmaceuticals, Livonia, MI 48152, NDC 68788-0841-01
Reason for Recall
CGMP Deviations: Potential product contamination with Burkholderia cepacia (B.cepacia) and Ralstonia pickettii (R. pickettii).
Distribution Pattern
Distribution was made to CA and FL.
Lot / Code Information
Lot: J0218L, Batch: 10021812, Exp. 02/2020; Lot: L2718D, Batch numbers from consecutively from L2718D001 to L2718D096, Exp. 07/2020
Other Recalls from Preferred Pharmaceuticals, Inc
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0797-2020 | Class II | Preferred Pharmaceuticals, Inc, Ranitidine Tabl... | Jan 7, 2020 |
| D-0796-2020 | Class II | Preferred Pharmaceuticals, Inc, Ranitidine Tabl... | Jan 7, 2020 |
| D-0617-2020 | Class II | Ranitidine Tablets, USP 150 mg, OTC, a.) 30 cou... | Dec 2, 2019 |
| D-0531-2020 | Class II | Ibuprofen Oral Suspension USP, 100 mg/5mL, 4 fl... | Nov 21, 2019 |
| D-1877-2019 | Class II | Fexofenadine HCl Tablets, 180 mg, Pkg Size 90, ... | Aug 29, 2019 |
Frequently Asked Questions
cGMP stands for Current Good Manufacturing Practice — the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful — in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.